These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 25256116)

  • 1. Personal reflections of a patient representative in an appraisal committee.
    Smit C
    Patient; 2015 Feb; 8(1):5-10. PubMed ID: 25256116
    [No Abstract]   [Full Text] [Related]  

  • 2. What impact does 'conventional' economic evaluation have on patient access to new orphan medicines? A comparative study of their reimbursement in Australia (2005-2012).
    Wonder M; Chin G
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):843-50. PubMed ID: 25938794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The many vs. the few.
    Loewenstein G
    Hastings Cent Rep; 2012; 42(5):7-8; author reply 8-9. PubMed ID: 23050293
    [No Abstract]   [Full Text] [Related]  

  • 4. The many vs. the few.
    Wells RJ
    Hastings Cent Rep; 2012; 42(5):7; author reply 8-9. PubMed ID: 23050292
    [No Abstract]   [Full Text] [Related]  

  • 5. The many vs. the few.
    Menzel PT
    Hastings Cent Rep; 2012; 42(5):5-6; author reply 8-9. PubMed ID: 23050290
    [No Abstract]   [Full Text] [Related]  

  • 6. Two dreams.
    Hastings Cent Rep; 2012; 42(1):2. PubMed ID: 22616382
    [No Abstract]   [Full Text] [Related]  

  • 7. How should we model rare disease allocation decisions?
    London AJ
    Hastings Cent Rep; 2012; 42(1):3. PubMed ID: 22616383
    [No Abstract]   [Full Text] [Related]  

  • 8. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
    Vegter S; Rozenbaum MH; Postema R; Tolley K; Postma MJ
    Clin Ther; 2010 Aug; 32(9):1651-61. PubMed ID: 20974323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lucrative niches: how drugs for rare diseases became lifeline for companies.
    Anand G
    Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531
    [No Abstract]   [Full Text] [Related]  

  • 10. How can the risk that orphan drugs present to budgets be managed better?
    O'Neill C
    Clin Ther; 2010 Aug; 32(9):1640-1. PubMed ID: 20974321
    [No Abstract]   [Full Text] [Related]  

  • 11. Which orphans will find a home? The rule of rescue in resource allocation for rare diseases.
    Largent EA; Pearson SD
    Hastings Cent Rep; 2012; 42(1):27-34. PubMed ID: 22616398
    [No Abstract]   [Full Text] [Related]  

  • 12. Access to orphan drugs in Europe: current and future issues.
    Michel M; Toumi M
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Access to orphan drugs in western Europe: can more systematic policymaking really help to avoid different decisions about the same drug?
    Kanters TA; Hakkaart L; Rutten-van Mölken MP; Redekop WK
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):557-9. PubMed ID: 25973903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uncertain miracle: a biotech drug extends a life, but at what price? For Ms. Lees, treatment bill now totals $7 million; her bones keep crumbling; guilt of another $1,400 day.
    Wall St J (East Ed); 2005 Nov; ():A1, A15. PubMed ID: 16502532
    [No Abstract]   [Full Text] [Related]  

  • 16. [Orphan drugs: availability, reliability and reimbursement].
    Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ
    Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. We need a "made in Canada" orphan drug framework.
    McMillan HJ; Campbell C
    CMAJ; 2017 Oct; 189(41):E1274-E1275. PubMed ID: 29038319
    [No Abstract]   [Full Text] [Related]  

  • 18. The many vs. the few.
    Zallen DT
    Hastings Cent Rep; 2012; 42(5):4-5; author reply 8-9. PubMed ID: 22976402
    [No Abstract]   [Full Text] [Related]  

  • 19. The many vs. the few.
    McCabe C
    Hastings Cent Rep; 2012; 42(5):6-7; author reply 8-9. PubMed ID: 23050291
    [No Abstract]   [Full Text] [Related]  

  • 20. Why orphan drug coverage reimbursement decision-making needs patient and public involvement.
    Douglas CM; Wilcox E; Burgess M; Lynd LD
    Health Policy; 2015 May; 119(5):588-96. PubMed ID: 25641123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.